AI assessment of tumor-infiltrating lymphocytes on routine H&E-slides as a predictor of response to neoadjuvant therapy in breast cancer-a real-world study.

This study evaluates tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers in triple-negative (T...

Continue ReadingAI assessment of tumor-infiltrating lymphocytes on routine H&E-slides as a predictor of response to neoadjuvant therapy in breast cancer-a real-world study.

Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects.

This phase Ib trial evaluated the ATR inhibitor elimusertib in 143 patients with advanced cancers exhibiting DNA damage...

Continue ReadingPhase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects.

The Honest Broker: Reimagining the Roles of Health Services Research, Community Partnership, and Policymaking to Address Structural Determinants of Cancer Outcomes.

This commentary highlights the evolution of health disparities research over the past 50 years, shifting from focusing o...

Continue ReadingThe Honest Broker: Reimagining the Roles of Health Services Research, Community Partnership, and Policymaking to Address Structural Determinants of Cancer Outcomes.